







an Open Access Journal by MDPI

Advances in Management of Urothelial Cancer

Guest Editor:

Prof. Dr. Shomik Sengupta

Eastern Health Clinical School, Monash University, 5 Arnold Street, Box Hill, VIC 3128, Australia

Deadline for manuscript submissions:

10 November 2024

Message from the Guest Editor

Dear Colleagues,

Urothelial cancers, particularly arising from the bladder, represent a large healthcare burden. On the one hand, lowrisk bladder cancers are common and can recur frequently. thus requiring long-term repetitive follow-up that is invasive and expensive. On the other hand, invasive bladder cancer and upper tract urothelial cancer (UTUC) are rarer but potentially lethal, hence require aggressive and morbid treatment in patients who are elderly or frail. New developments in diagnostic modalities of endoscopy. imaging, biomarkers and genomics have come about in recent years, achieving earlier diagnoses and precise classification and prognostication. In parallel, there is an increased availability of therapeutic options in terms of improved surgical tools and approaches as well as novel targeted agents delivered systemically endoluminally. This Special Issue will highlight many of these developments. We welcome reviews of the current status of this field, as well as original research related to the management of urothelial cancer.

Prof. Dr. Shomik Sengupta *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us